相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
Tetsu Tomonari et al.
CANCER MEDICINE (2023)
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib
Atsushi Hiraoka et al.
CANCER MEDICINE (2023)
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma
Aditya Juloori et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song et al.
CLINICAL CANCER RESEARCH (2023)
Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis
Toshifumi Tada et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2022)
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Kazuki Maesaka et al.
HEPATOLOGY RESEARCH (2022)
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis
Makoto Chuma et al.
HEPATOLOGY RESEARCH (2022)
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis
Atsushi Hiraoka et al.
HEPATOLOGY RESEARCH (2022)
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa et al.
INVESTIGATIONAL NEW DRUGS (2022)
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann-Lii Cheng et al.
JOURNAL OF HEPATOLOGY (2022)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau et al.
LANCET ONCOLOGY (2022)
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2022)
Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC
Sara Lewis et al.
ABDOMINAL RADIOLOGY (2022)
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
Jing-Houng Wang et al.
CANCERS (2022)
Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma
Ryu Sasaki et al.
CANCERS (2022)
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life
Ion Agirrezabal et al.
ADVANCES IN THERAPY (2022)
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma
Shohei Komatsu et al.
ANTICANCER RESEARCH (2022)
Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications
Xuqi Sun et al.
BMC CANCER (2022)
Lenvatinib plus pembrolizumab for systemic therapy-naive and -experienced unresectable hepatocellular carcinoma
Chi-Jung Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab plus Bevacizumab Treatment of Hepatocellular Carcinoma
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2022)
Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
Song Chen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma
Grace L. Su et al.
GASTROENTEROLOGY (2022)
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice
Takaaki Tanaka et al.
HEPATOLOGY RESEARCH (2022)
Monoclonal antibodies for malaria prevention
Maya Aleshnick et al.
MOLECULAR THERAPY (2022)
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2022)
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
Toshifumi Tada et al.
CANCER MEDICINE (2022)
Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies
Yawen Jiang et al.
CLINICAL EPIDEMIOLOGY (2022)
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
Beom Kyung Kim et al.
CANCERS (2022)
Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma
Gohar Shahwar Manzar et al.
CANCERS (2022)
Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab
Ying Xu
FRONTIERS IN ONCOLOGY (2022)
Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
Evgenia Kotsifa et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma
Eleni-Myrto Trifylli et al.
LIFE-BASEL (2022)
Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review
Christos Damaskos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors
Benedetta Stefanini et al.
DIGESTIVE AND LIVER DISEASE (2022)
Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives
Evangelos Koustas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Andrew X. Zhu et al.
NATURE MEDICINE (2022)
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy
Takayuki Matsumae et al.
CANCERS (2022)
Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
Hiroaki Matsumoto et al.
CANCERS (2022)
Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
Katsuya Toshida et al.
JGH OPEN (2022)
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi et al.
EUROPEAN JOURNAL OF CANCER (2022)
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Mathew Vithayathil et al.
LIVER INTERNATIONAL (2022)
Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Richard J. Sove et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma
Yusuke Kawamura et al.
ONCOLOGY (2022)
Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
Takashi Tanaka et al.
CURRENT ONCOLOGY (2022)
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience
Keita Ogawa et al.
JOURNAL OF CANCER (2022)
Emerging new therapeutic antibody derivatives for cancer treatment
Shijie Jin et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
Atsushi Hiraoka et al.
GASTROENTEROLOGY REPORT (2021)
Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study
Song Chen et al.
BMC CANCER (2021)
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
Kayoko Kasuya et al.
INTERNAL MEDICINE (2021)
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states
Feng Wen et al.
LIVER INTERNATIONAL (2021)
Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison
Andrea Casadei-Gardini et al.
TARGETED ONCOLOGY (2021)
First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Chi-Leung Chiang et al.
CANCERS (2021)
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
Dan Su et al.
JAMA NETWORK OPEN (2021)
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Shukui Qin et al.
LIVER CANCER (2021)
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Xin Zhang et al.
JAMA NETWORK OPEN (2021)
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
Nikolaos Garmpis et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
Antonio D'Alessio et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
Takuya Sho et al.
HEPATOLOGY RESEARCH (2021)
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Peter R. Galle et al.
LANCET ONCOLOGY (2021)
Characterization of response to atezolizumab plus bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
Riad Salem et al.
CANCER MEDICINE (2021)
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
Colby S. Shemesh et al.
LIVER CANCER (2021)
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
Yuwa Ando et al.
CANCERS (2021)
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Hideki Iwamoto et al.
CANCERS (2021)
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
Yuji Eso et al.
CURRENT ONCOLOGY (2021)
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy
Kei Amioka et al.
ONCOLOGY (2021)
Hepatocellular carcinoma, novel therapies on the horizon
Imane El Dika et al.
CHINESE CLINICAL ONCOLOGY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab
Tomokazu Kawaoka et al.
HEPATOLOGY RESEARCH (2020)
Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
Pei-Chang Lee et al.
CANCERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
Pil Soo Sung et al.
FRONTIERS IN ONCOLOGY (2020)
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee et al.
LANCET ONCOLOGY (2020)
Child Pugh and ALBI grade: past, present or future?
Margherita Rimini et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma
Ze-Long Liu et al.
Aging-US (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
Lynn G. Feun et al.
CANCER (2019)
Durvalumab in cancer medicine: a comprehensive review
Juliana Alvarez-Argote et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
Lorraine Pelosof et al.
ONCOLOGIST (2018)
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Giorgia Marisi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
Rhian M. Touyz et al.
NPJ PRECISION ONCOLOGY (2018)
Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis
Alessandro Granito et al.
LANCET ONCOLOGY (2017)
PharmGKB summary: sorafenib pathways
Li Gong et al.
PHARMACOGENETICS AND GENOMICS (2017)
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world
Dimitrios Dimitroulis et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Liting Guo et al.
JOURNAL OF CANCER (2017)
Immune Checkpoint Inhibitors in Challenging Populations
Douglas B. Johnson et al.
CANCER (2017)
Pembrolizumab (Keytruda)
Gerry Kwok et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
Sanjaykumar Hapani et al.
ONCOLOGY (2010)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)